Ajinomoto (AJINY) announced a license agreement with Exelixis (EXEL) to incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis’ antibody-drug conjugate programs. As part of the license agreement, Exelixis will have the right to use the AJICAP technology to support its aim of advancing multiple ADCs with the potential for higher efficacy and lower toxicity than currently available options. Ajinomoto Co. is eligible to receive development, regulatory and commercial milestone payments as well as royalties on commercial sales.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EXEL:
- Exelixis price target lowered to $20 from $21 at Cowen
- Exelixis reports preliminary Q4 revenue $415M, consensus $414.83M
- NccRCC ‘material expansion opportunity’ for Exelixis, says William Blair
- Exelixis announces initiation of STELLAR-304 Phase 3 trial of zanzalintinib
- Exelixis names Dana Aftab next chief scientific officer